SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT

1 - 26 . (canceled)

27 . A pharmaceutical formulation comprising:

omecamtiv mecarbil, or a pharmaceutically acceptable salt, a pharmaceutically acceptable hydrate, or a pharmaceutically acceptable hydrate of a salt thereof;

a control release agent;

a pH modifying agent;

a filler; and

a lubricant.

28 . The pharmaceutical formulation of claim 27 , comprising:

omecamtiv mecarbil dihydrochloride hydrate;

a control release agent selected from the group consisting of pulluan, dextrin, sodium and calcium acid, polyacrylic acid, polymethacrylic acid, polymethylvinylether co-maleic anhydride, polyvinylpyrrolidone, polyethylene oxide, polyethylene glycol, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxymethyl methacrylate, sodium carboxymethylcellulose, calcium carboxymethylcellulose, methylcellulose, maltodextrin, xanthan gum, tragacanth gum, agar, gellan gum, kayara gum, alginic acids, pectins, pre-gelatinized starch, polyvinyl alcohol, carboxymethylethylcellulose, cellulose acetate phthalate, cellulose acetate succinate, methylcellulose phthate, hydroxymethylethylcellulose phthate, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, polyvinyl alcohol phthalate, polyvinyl butylate phthalate, polyvinyl actal phthalate, a copolymer of vinyl acetate/maleic anhydride, a copolymer of styrene/maleic acid monoester, a copolymer of methyl acrylate/methacrylic acid, a copolymer of styrene/acrylic acid, a copolymer of methyl acrylate/methacrylic acid/octyl acrylate, a copolymer of methacrylic acid/methyl methacrylate, benzylaminomethylcellulose, diethylaminomethylcellulose, piperidylethylhydroxyethylcellulose, cellulose acetate dimethylaminoacetate, a copolymer of vinyl diethylamine/vinyl acetate, a copolymer of vinyl benzylamine/vinyl acetate, polyvinyl acetal diethylamino acetate, a copolymer of vinylpiperidylacetoacetal/vinyl acetate, polydiethylaminomethylstyrene, a copolymer of methyl methacrylate/butyl methacrylate/dimethylaminoethyl methacrylate and polydimethylaminoethylmethacrylate, a copolymer of 2-methy-5vinylpyrid-ine/methylmethacrylate/methacrylic acid, a copolymer of 2-methyl-5-vinylpyridine/methyl acrylate/methacrylic acid, a copolymer of 2-vinyl-5-ethylpyridine/methacrylic acid/methy acrylate, a copolymer of 2-vinylpyrid-ine/methacrylic acid/acrylonitrile, carboxymethylpiperidyl starch, carboxy-methylbenzylaminocellulose, a copolymer of N-vinylglycine/styrene, chitosan, poly(vinyl alcohol), maleic anhydride copolymer, poly (vinyl pyrolidone), starch and starch-based polymers, poly (2-ehtyl-2-oxazoline), poly(ethyleneimine), polyurethane hydrogels, welan gum, rhamsan gum, polyvinyl acetates, ethylcellulose, or any combination thereof;

a pH modifying agent selected from the group consisting of maleic acid, citric acid, malic acid, fumaric acid, sulfuric acid, tartaric acid, lactoic acid, salicylic acid, aspartic acid, aminosalicylic acid, malonic acid, glutamic acid, and any combination thereof;

a filler; and

a lubricant selected from the group consisting of stearic acid, hydrogenated vegetable oil, hydrogenated soybean oil, hydrogenated soybean oil, castor wax, stearyl alcohol, leucine, polyethylene glycol, magnesium stearate, glyceryl monostearate, stearic acid, glycerybehenate, polyethylene glycol, ethylene oxide polymers, sodium lauryl sulfate, magnesium lauryl sulfate, sodium oleate, sodium stearyl fumarate, DL-leucine, colloidal silica, or any mixture thereof.

29 . The pharmaceutical formulation of claim 28 , wherein the formulation comprises:

3-10% w/w omecamtiv mecarbil dihydrochloride hydrate;

1-10% w/w Methocel™ K100 M Prem CR;

12-27% w/w Methocel™ K100 LV Prem CR;

30-50% w/w microcrystalline cellulose, PH 102;

15-25% w/w lactose monohydrate, FF 316;

3-11% w/w fumaric acid;

0.1-2% w/w intra-granular magnesium stearate; and

0.1-2% w/w extra-granular magnesium stearate.

30 . The pharmaceutical formulation of claim 28 , wherein the formulation comprises:

18-19% w/w omecamtiv mercarbil dihydrochloride hydrate;

28-32% w/w Methocel™ K100 M Prem CR;

23-26% w/w microcrystalline cellulose, PH 102;

7-9% w/w lactose monohydrate, FF 316;

17-20% w/w fumaric acid;

0.1-2% w/w intra-granular magnesium stearate; and

0.1-2% w/w extra-granular magnesium stearate.

31 . The pharmaceutical formulation of claim 28 , wherein the formulation comprises:

5-7% w/w omecamtiv mercarbil dihydrochloride hydrate;

3-7% w/w Methocel™ K100 M Prem CR;

18-22% w/w Methocel™ K100 LV Prem CR;

37-43% w/w microcrystalline cellulose, PH 102;

18-22% w/w lactose monohydrate, FF 316;

6-9% w/w fumaric acid;

0.1-1% w/w intra-granular magnesium stearate; and

0.1-1% w/w extra-granular magnesium stearate.